Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SER-A-GEN vs ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SER-A-GEN is a serotonin receptor agonist that selectively activates 5-HT1A and 5-HT2A receptors, modulating neurotransmitter release in the central nervous system.
Chloroquine and primaquine: Chloroquine inhibits heme polymerase in malaria parasites, preventing conversion of toxic heme to hemozoin; primaquine disrupts mitochondrial function and generates reactive oxygen species, targeting hypnozoites and gametocytes.
Major Depressive Disorder,Generalized Anxiety Disorder,Obsessive-Compulsive Disorder (off-label)
Treatment of acute attacks of vivax malaria due to Plasmodium vivax,Radical cure of vivax malaria (elimination of hypnozoites),Suppression of malaria (prophylaxis) in areas with chloroquine-sensitive P. vivax
500 mg orally once daily.
Chloroquine phosphate 600 mg base (1 g salt) orally once daily for 2 days, then 300 mg base (500 mg salt) once daily for at least 2 weeks; plus primaquine phosphate 30 mg base orally once daily for 14 days.
8 ± 2 hours; prolonged to 20-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Chloroquine: 40-60 days (terminal); Primaquine: 6-8 hours (terminal). Clinical context: chloroquine accumulates extensively, requiring prolonged monitoring for toxicity; primaquine, shorter half-life, once-daily dosing.
Hepatic via CYP3A4 and CYP2D6 isoenzymes; undergoes glucuronidation to inactive metabolites.
Chloroquine: hepatic metabolism via CYP2C8 and CYP3A4; primaquine: hepatic metabolism via CYP2D6 and other enzymes.
Primarily renal: 70% unchanged drug; 20% as glucuronide conjugate; <5% fecal.
Renal: 70% (chloroquine as unchanged drug and metabolites), 20% (primaquine as metabolites); Fecal: ~10% (chloroquine); Biliary: minor for both.
92% primarily to albumin; also binds α1-acid glycoprotein.
Chloroquine: 50-65% bound to albumin; Primaquine: ~20% bound to albumin.
0.45 ± 0.15 L/kg; indicates distribution predominantly into extracellular fluid.
Chloroquine: Vd 100-200 L/kg (extensive tissue distribution); Primaquine: Vd 3-5 L/kg (moderate distribution). Clinical meaning: large Vd of chloroquine indicates deep tissue compartments with slow release.
Oral: 65-75% with first-pass metabolism; intramuscular: 100%.
Both: Oral bioavailability ~80-90% for chloroquine; ~90% for primaquine. No parenteral form for this combination.
GFR 30-50 m L/min: 250 mg once daily; GFR <30 m L/min: 250 mg every other day; dialysis: 250 mg three times weekly after dialysis.
For chloroquine: GFR 10-50: 50% dose; GFR <10: 25% dose. For primaquine: No adjustment required, but monitor for hemolysis in GFR <10 due to accumulation.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: use not recommended.
For chloroquine: Child-Pugh A/B: no adjustment; Child-Pugh C: reduce dose by 50% or avoid. For primaquine: Child-Pugh A/B: no data, use with caution; Child-Pugh C: contraindicated due to risk of hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficiency and impaired clearance.
Weight ≥10 kg: 10 mg/kg orally once daily; maximum 500 mg daily.
Chloroquine: 10 mg base/kg orally once daily for 2 days, then 5 mg base/kg once daily (max 300 mg base/day) for 2 weeks. Primaquine: 0.5 mg base/kg orally once daily for 14 days (max 30 mg base/day). Ensure G6PD screening before use.
No specific dose adjustment; monitor renal function and reduce dose per renal adjustment if Cr Cl <50 m L/min.
Use lower end of adult dose for chloroquine due to reduced renal function; adjust according to Cr Cl. For primaquine, monitor for G6PD deficiency and hemolysis; dose as per adult. Consider increased risk of QT prolongation with chloroquine.
None
Primaquine may cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Test for G6PD deficiency before starting therapy.
Serotonin syndrome risk when co-administered with other serotonergic drugs; QT prolongation at high doses; hepatic impairment requires dose adjustment; discontinuation syndrome upon abrupt cessation.
Hemolytic anemia (especially G6PD deficiency), bone marrow suppression, prolonged QT interval, visual disturbances (retinopathy with chloroquine), methemoglobinemia, and severe hypersensitivity reactions.
Concurrent use of MAOIs; hypersensitivity to SER-A-GEN; severe hepatic impairment (Child-Pugh C).
G6PD deficiency (primaquine), known hypersensitivity to chloroquine or primaquine, porphyria, concurrent use of drugs with known hemolytic potential, pregnancy (based on risk-benefit), and severe liver or kidney disease.
Avoid grapefruit and grapefruit juice as they may increase serum levels and risk of toxicity. No other significant food interactions known; take with or without food.
No clinically significant food interactions reported. However, antacids containing magnesium or aluminum can reduce chloroquine absorption; separate administration by at least 4 hours. Grapefruit juice may increase chloroquine levels via CYP3A4 inhibition; avoid concurrent use.
First trimester: Associated with neural tube defects (NTDs), cardiovascular malformations, and oral clefts. Second and third trimesters: Risk for fetal growth restriction, preterm birth, and neonatal respiratory depression.
In first trimester, chloroquine is generally considered low risk for major malformations, but primaquine is contraindicated due to risk of hemolytic anemia in G6PD-deficient fetuses. Second and third trimesters: chloroquine is safe, but primaquine should be avoided as fetal G6PD status is unknown.
Excreted into breast milk in low concentrations; M/P ratio 0.25. Potential for infant sedation and poor feeding. Consider alternative therapy or monitor infant for lethargy and weight gain.
Chloroquine is excreted into breast milk in low concentrations; M/P ratio is approximately 0.5-0.6. Primaquine is excreted in breast milk; M/P ratio not well established. Breastfeeding is generally considered safe if infant is G6PD normal, but caution is advised due to potential for hemolysis in G6PD-deficient infants.
Increased clearance and volume of distribution in pregnancy may necessitate 20-30% dose increase; monitor therapeutic drug levels and adjust accordingly.
Chloroquine: No dose adjustment required; pharmacokinetics are not significantly altered. Primaquine: Contraindicated in pregnancy due to risk of hemolytic anemia in the fetus; no dose adjustment is applicable as it is not recommended.
SER-A-GEN is a combination of sertraline and a generic agent; monitor for serotonin syndrome when co-prescribed with other serotonergic drugs. Use with caution in patients with hepatic impairment; start at lower doses. Abrupt discontinuation may cause withdrawal symptoms; taper gradually.
Combination of chloroquine and primaquine is used for radical cure of P. vivax and P. ovale malaria. Chloroquine is effective against blood-stage parasites; primaquine eradicates hypnozoites in the liver. Screen for G6PD deficiency before initiating primaquine to prevent hemolytic anemia. Concurrent use with hematotoxic drugs (e.g., dapsone) increases hemolysis risk. Contraindicated in G6PD-deficient patients, pregnancy, and breastfeeding unless no alternative. Monitor for QT prolongation, especially with electrolyte abnormalities or concurrent QT-prolonging agents.
Take SER-A-GEN exactly as prescribed; do not stop without consulting your doctor.,It may take several weeks to feel the full benefit; continue taking it even if you feel well.,Avoid alcohol while taking this medication.,Report any symptoms of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate, fever, muscle stiffness) immediately.,Do not take with other antidepressants or migraine medications without medical advice.
Take with food or milk to reduce gastrointestinal upset.,Complete full course regardless of symptom resolution to prevent relapse.,Avoid alcohol during treatment due to risk of disulfiram-like reaction.,Report signs of hemolysis: dark urine, jaundice, pallor, fatigue (especially if G6PD deficient).,Do not take antacids containing magnesium or aluminum within 4 hours of chloroquine as they reduce absorption.,Seek medical attention for visual disturbances, QT prolongation symptoms (palpitations, syncope), or severe GI distress.,Use effective contraception during and for 1 month after treatment due to potential fetal harm from primaquine.
No interactions on record
"Alimemazine, a phenothiazine derivative with antihistaminergic and anticholinergic properties, may inhibit the metabolism of Primaquine, an antimalarial agent primarily metabolized by cytochrome P450 enzymes including CYP2D6 and CYP3A4. This interaction can lead to increased plasma concentrations of Primaquine, heightening the risk of dose-dependent adverse effects such as hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and methemoglobinemia. Clinically, patients may present with signs of oxidant stress, including hemoglobinuria and jaundice."
"Eliglustat, a CYP2D6 substrate and inhibitor, can increase the systemic exposure of primaquine, which is primarily metabolized by CYP2D6. This elevation in primaquine concentration may potentiate its QTc-prolonging effects, leading to an increased risk of torsades de pointes and other ventricular arrhythmias. Caution is advised, especially in patients with pre-existing cardiac conditions or electrolyte abnormalities."
"Primaquine, an antimalarial agent, can inhibit the cardiac potassium channel encoded by the hERG gene, leading to prolongation of the QTc interval. Ivabradine, a funny current (If) inhibitor used for chronic heart failure, also possesses a mild QTc-prolonging effect. Concomitant use increases the risk of excessive QTc prolongation, which may precipitate torsade de pointes and other ventricular arrhythmias, particularly in patients with underlying risk factors such as electrolyte disturbances or bradycardia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SER-A-GEN vs ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE, answered by our medical review team.
SER-A-GEN is a Antihypertensive Combination that works by SER-A-GEN is a serotonin receptor agonist that selectively activates 5-HT1A and 5-HT2A receptors, modulating neurotransmitter release in the central nervous system.. ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is a Antimalarial that works by Chloroquine and primaquine: Chloroquine inhibits heme polymerase in malaria parasites, preventing conversion of toxic heme to hemozoin; primaquine disrupts mitochondrial function and generates reactive oxygen species, targeting hypnozoites and gametocytes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SER-A-GEN and ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SER-A-GEN is: 500 mg orally once daily.. The standard adult dose of ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is: Chloroquine phosphate 600 mg base (1 g salt) orally once daily for 2 days, then 300 mg base (500 mg salt) once daily for at least 2 weeks; plus primaquine phosphate 30 mg base orally once daily for 14 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SER-A-GEN and ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SER-A-GEN is classified as Category C. First trimester: Associated with neural tube defects (NTDs), cardiovascular malformations, and oral clefts. Second and third trimesters: Risk for fetal growth restriction, preterm . ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is classified as Category D/X. In first trimester, chloroquine is generally considered low risk for major malformations, but primaquine is contraindicated due to risk of hemolytic anemia in G6PD-deficient fetuse. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.